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After acute hepatitis B virus (HBV) infection 5–
10% of all adult patients become chronically in-
fected; the mechanism of the viral persistence in
this minority of patients remains unclear. In pa-
tients with an acute self-limiting HBV infection a
vigorous T-lymphocyte response to the core anti-
gen and a weaker response to the surface antigen
are observed (1, 2). It is suggested that the produc-
tion of Th1-type pro-inflammatory cytokines
(gamma-interferon (IFN-g) interleukin-2 (IL-2)
and tumour necrosis factor-alpha (TNF-a)) is
mainly instrumental in inducing viral clearance (3).
Viral persistence on the other hand is associated
with T-cell hyporesponsiveness possibly due to
exhaustion or paralysis of the immune system due
to overwhelming antigen presentation (1, 4). Re-
combinant alpha interferon therapy successfully
inhibits viral replication in about 30% of the pa-
tients with chronic hepatitis B by means of the di-
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rect antiviral effects of the drug or by inducing an
HBV-specific immune response (5).
Hepatitis A virus (HAV) is transmitted enterally.
In highly endemic areas it causes a mild self-limit-
ing hepatitis among young children. In countries
of low endemicity infection occurs at an older age.
This is associated with a much higher case fatality
rate especially among adults over 40 years of age
(6). In patients with underlying chronic liver dis-
eases such as chronic hepatitis C, HAV infection
can lead to fulminant hepatitis and death (7, 8).
Data on the impact of HAV infection on chronic
HBV are contradictory (7–9). HAV superinfection
has been reported to have an inhibitory effect on
HBV replication during the acute phase of HAV.
Several antiviral mechanisms have been postulated
to explain the drop in HBV protein production: a
direct effect of the reduction in target cells follow-
ing hepatic necrosis or viral interference, or an in-
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direct effect due to HAV-induced cytokine produc-
tion (9–13).
During an HAV outbreak among homosexual
men in the Rotterdam area we studied a chronic
hepatitis B patient during an early phase of acute
HAV infection in detail.
Materials and methods
Viral serology
Diagnosis of acute HAV infection was based on a
highly positive IgM-anti HAV test (IMX Abbott
Chicago, IL). Co-infections with CMV EBV HDV
and HIV were excluded by standard serology.
Acute HCV infection was excluded by PCR.
HBV DNA was measured by liquid hybridiza-
tion (Digene II, Murex, UK) and, if negative, by
PCR (detection limit 400 genome equivalents per
ml (gen Equiv/ml) based on the Eurohep stan-
dard). HBeAg (IMX, Abbott) and HBsAg
(AxSYM HBsAg, Abbott) were measured quanti-
tatively and expressed in Paul Ehrlich Units.
Measurement of serum cytokine levels
Sequential serum samples before and during the
acute hepatitis episode have been tested for levels
Fig. 1. Patient with chronic hepatitis B infected with HAV during lamivudine treatment. A sudden drop in HBV DNA was observed
in combination with a hepatitis flare followed by loss of HBeAg. An interferon-gamma peak preceded the rise in serum transaminase
activity.
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of circulating IFN-a, IFN-g, IL-10, IL-12, and
TNF-a by means of the standard sandwich ELISA
technique. Antibodies for coating and detection,
and ELISA reagents were obtained from the fol-
lowing: HyCult biotechnology, Uden, The Nether-
lands (anti-IFN-a); Medgenix Diagnostics,
Fleurus, Belgium (anti-IFN-g); Pharmingen, San
Diego, CA, USA (anti-IL10); R&D Systems, Min-
neapolis, MN, USA (anti-IL12); and CLB,
Amsterdam, The Netherlands (TNF-a). Lower de-
tection limits in each assay were: IFN-a, 50 pg/ml;
IFN-g, 10 pg/ml; IL-10, 20 pg/ml; IL-12, 80 pg/ml;
TNF-a, 4 pg/ml.
Antigens
Recombinant C-terminal truncated HBcAg par-
ticles (146aa) expressed in E. coli (American Re-
search Products, Belmont, MA, USA; cat no.12–
3069, batch r-HBcAg-e-CIT-0070) were used in
lymphocyte stimulation assays. As control antigen,
recombinant HCV NS3 protein, also expressed in
E. coli (American Research Products, cat. no.12–
00117, batch 9812ns3) was used. Recombinant pre-
S1- and pre-S2-containing HBsAg particles, ex-
pressed in Chinese hamster ovary (CHO) cells,
were obtained from Dr Reinhard Gluck (Swiss
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Serum and Vaccine Institute Berne, Berne, Switz-
erland).
In vitro lymphocyte proliferation assays
Ag-specific lymphocyte proliferative response
(LPR) was measured retrospectively culturing 105
thawed peripheral blood mononuclear cells
(PBMC) in four replicate round-bottom microtitre
wells for 7 days in 0.1 ml RPMI-1640 supple-
mented with antibiotics and 10% human pooled
serum in the presence of one of the above de-
scribed antigens. Optimal Ag concentration was
determined as 2 mg/ml according to titrations per-
formed on PBMC from patients with acute hepa-
titis B and healthy blood donors, either HBsAg-
vaccinated or not. [3H]-Thymidine (specific activity
5 mCi/mmol) was added for the last 20 h of culture
and the incorporated radioactivity measured in a
b-scintillation counter. Results were expressed as
counts per minute (cpm) and the lymphocyte
stimulation index (LSI) was calculated as the ratio
between median cpm in the HBcAg- or HBsAg-
containing cultures and median cpm of cultures
containing HCV NS3 or no added Ag, respectively.
The 99th percentile of HBcAg-specific SI in 10
healthy blood donors was 2.29. For practical pur-
poses, specific LPR was scored positive when
LSI.3.
Results
A 33-year-old homosexual man was known to have
been HBeAg-positive since 1995. He was a non-
responder to a previous 4-month course of alpha
interferon in 1996. Lamivudine (150 mg once
daily) was started in August 1997 and the patient
was included in a standardised monthly follow-up
protocol. The initial drop in HBV DNA ceased
after 8 weeks of treatment but HBV DNA re-
mained detectable at levels around 107–106 gen
Equiv/ml (Fig. 1).
After 24 weeks of lamivudine therapy ALAT,
ASAT and bilirubin rose to peak levels of 3061
U/l, 1764 U/l and 202 mmol/l, respectively. He was
jaundiced and complained of malaise, lack of
appetite and fatigue. There was neither alcohol nor
drug abuse. The differential diagnosis included la-
mivudine resistance, drug toxicity, spontaneous
clearance of hepatitis B, and a post-lamivudine
flare due to non-compliance or superinfection with
HAV, HCV or HDV.
Compliance with his lamivudine medication was
demonstrated excluding a lamivudine-withdrawal
flare. He did not use nor had ever used other drugs.
No evidence of HCV or HDV was found. A YMDD
analysis showed wild-type hepatitis B virus.
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Table I. HBcAg-specific LPR of the control population versus the LPR over
time of the acute HAV-infected CHB patient
HBc-LSI LSI SE
Controls Healthy donors (nΩ10) 1.3700 0.1400
AHB (nΩ11) 4.2100 0.9700
CHB (nΩ16) 2.1400 0.2900
Patient Week 0 (start lamivudine) 2.8600
Week 4 3.7600
Week 48 (after acute HAV) 4.9000
AHB: acute hepatitis B. CHB: chronic hepatitis B. SE: standard error.
Extensive virological testing documented an
acute HAV superinfection. IgM anti-HAV was de-
tectable in serum at the moment serum transamin-
ase activity started to increase. Peak serum levels
of naturally produced IFN-g, but also IL-10, were
measurable just before the rise in serum transamin-
ase activity and the subsequent drop in HBV DNA
levels (Fig. 1). In these samples the levels of IFN-
a, TNF-a and IL-12 were below the level of detec-
tion. The proliferative response of PBMC’s against
the hepatitis B core antigen was already detectable
before the acute hepatitis, after lamivudine therapy
was started and showed no significant change after
the acute HAV infection (Table 1). No HBsAg-spe-
cific response could be measured in these samples.
During the next 2 months HBV DNA dropped
further below the level of PCR detection. HBeAg
and anti-HBe reached borderline values, HBsAg
remained detectable at very low levels and serum
transaminases dropped to normal.
After seroconversion alpha interferon therapy
was started to induce a sustained HBeAg serocon-
version with detectable anti-HBe antibodies. After
8 weeks of combination therapy lamivudine was
withdrawn; HBV DNA subsequently became de-
tectable. After 12 weeks of IFN monotherapy anti-
HBe antibodies were detectable; IFN was given for
a total period of 20 weeks. However, after its with-
drawal, HBeAg relapsed.
Discussion
Acute hepatitis A infection has been reported to
suppress hepatitis B viral replication in several
cases (9–13). In acute hepatitis A lysis of infected
hepatocytes is mainly a T-cell-mediated cytotoxic
mechanism rather than a direct cytopathic effect
of the virus (14–16). It has been suggested that
massive necrosis of infected hepatocytes leads to
the decrease in HBV DNA (11–13). Hepatitis A
caused massive necrosis of infected hepatocytes in
our patient, resulting in elevated transaminase ac-
tivity followed by clearance of HBV DNA and
HBeAg. However, it is unlikely that cell necrosis of
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HBV-infected hepatocytes mediated by HAV-speci-
fic cytotoxic T lymphocytes eliminates all HBV-in-
fected hepatocytes.
The contribution of noncytolytic antiviral ef-
fects may be of major importance for viral clear-
ance in HBV (17). HAV-induced cytokine produc-
tion is one of the mechanisms that might cause
HAV-induced suppression of HBV replication (11,
18). IgM anti-HAV positivity coincided with the
high production of IFN-g followed by inhibition
of HBV DNA replication. In vitro data suggest
that IFN-g is the main effective mediator in acute
HAV infection. The effects occur at three levels:
stimulation of HLA antigen expression, direct vi-
rus-specific antiviral effects and immunomodulato-
ry effects (19). Acute self-limited HBV is probably
also mediated by predominantly Th1 cytokine pro-
duction, especially of IFN-g (3). Furthermore, in-
creased IL-12 levels are associated with HBeAg
seroconversion (20).
In this case HAV-specific IFN-g, focused on in-
fected hepatocytes, probably caused the drop in
HBV DNA. An IFN-a peak, as found by Davis et
al. (11), could not be confirmed; TNF-a and IL-
12 were also below the level of detection. At the
same time the production of IL-10, an immune-
regulating and anti-inflammatory Th2-cytokine,
was stimulated, probably contributing to the self-
limitation of the response.
Induction of an HBV-specific response would
possibly prevent relapse of the HBV infection.
Chronic HBV is associated with a weak and inef-
fective antiviral T-cell response to nucleocapside
antigens (HBcAg and HBeAg) in contrast to the
strong response in acute HBV infection (1, 3). In
acute exacerbations, spontaneous clearance and
response to alpha interferon therapy, a re-activated
T cell response is measurable, necessary for viral
elimination (21–23). Restoration of nucleocapside-
specific T cell response has been described also
during lamivudine treatment (4), but the underly-
ing mechanism and its clinical meaning are still un-
clear. Studies in a transgenic mouse model suggest
a relevant role for non-cytolytic IFN-g and TNF-
a-mediated suppression of HBV genome express-
ion exerted by HBsAg-specific CTLs (24).
In our patient there was already a pre-existing
weak LPR against HBcAg when lamivudine ther-
apy was started. As expected no response to the
surface antigen was detectable. The LPR did not
increase after the acute HAV infection, when meas-
ured in peripheral blood. This does not exclude an
increased response because of the possible com-
partmentalization of stimulated T-cells in the liver
(2). However this is not very likely in our patient
in view of his relapse after withdrawal of therapy.
HAV-induced production of IFN-g probably in-
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duced HBV DNA and HBeAg negativity. How-
ever, this was not combined with stimulation of
an HBV-specific T-cell memory which is probably
necessary to maintain HBe-seroconversion and
protection against HBV relapse. In conclusion we
think that our observations may contain import-
ant implications for specific immunotherapy for
chronic HBV patients on nucleoside analogue
therapy.
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